Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
LAKESIDE LAB
Original Assignee
LAKESIDE LAB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by LAKESIDE LABfiledCriticalLAKESIDE LAB
Priority to FR881992ApriorityCriticalpatent/FR1703M/fr
Application grantedgrantedCritical
Publication of FR1703MpublicationCriticalpatent/FR1703M/fr
C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
C07D333/06—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
C07D333/14—Radicals substituted by singly bound hetero atoms other than halogen
C07D333/20—Radicals substituted by singly bound hetero atoms other than halogen by nitrogen atoms
Landscapes
Chemical & Material Sciences
(AREA)
Organic Chemistry
(AREA)
FR881992A1961-12-141961-12-14Médicament a base de dérivé basique de butynol, en particulier pour le traitement de troubles gastro-intestinaux.
ExpiredFR1703M
(fr)
Médicament a base d'une nouvelle série de 1-aryl-4-oxo-1,3,8-triazaspiro-(4,5)-décanes, substitués en position 8 ou leurs sels pour le traitement d'affections mentales.
Médicament a base de 17-acétate de la 6 alpha-méthyl-9 alpha-fluoro-11 béta, 17 alpha-dihydroxy-1,4-prégnadiene-3,20-dione pour le traitement de l'aménorrhée.